MINNEAPOLIS, March 31, 2022 /PRNewswire/ — 4C Professional medical Technologies, Inc. (“4C Healthcare” or the “Company”), a privately-held professional medical engineering organization targeted on the progress of minimally invasive therapies for structural coronary heart disease, announced that it has completed a $35.4 million Series C Most well-liked Stock financing. The Sequence C round was led by MicroPort CardioFlow Medtech Corporation (HKEX:2160).
As section of the closing, 4C Medical also announced the appointment of Saravana Kumar, PhD as its President & Chief Executive Officer. Dr. Kumar has served as the Company’s interim President and CEO since March 2021 right after having beforehand served as the Company’s Vice President of R&D and Operations due to the fact November 2017.
“We are pleased to have an individual as targeted and goal-oriented as Dr. Kumar primary our organization to the next development stage, focusing on the even further enchancement of our transseptal supply procedure, together with the introduction of the subsequent technology lower profile procedure, and continuing medical evidence gathering for our AltaValve transcatheter mitral valve substitute (TMVR) gadget,” said Dr. Jeff Chambers, Founder and Chairman of the Board of 4C Healthcare.
“We are grateful for all the interest and assist we obtained from our buyers. The substantial money raised in the Collection C spherical furtherhkex emphasizes the value of continuing to develop our AltaValve® TMVR technologies and highlight its differentiated layout and ability to grow the treatable affected individual inhabitants working with our streamlined techniques,” explained Dr. Kumar. “The cash will also allow for us to broaden our product portfolio with the initiation of our tricuspid system.”
About 4C Professional medical Systems, Inc.
4C Clinical is a healthcare machine company establishing minimally invasive systems for structural heart ailment, concentrating to begin with on mitral regurgitation (MR) treatment and subsequently on tricuspid regurgitation therapy. Subject matter to regulatory approvals, the Firm’s AltaValve® would be the initial MR remedy with atrial-only fixation that is made to lessen identified troubles linked with current TMVR systems, which depend on placement and fixation within just the native mitral annulus.
Media Contacts
|
Saravana Kumar, PhD President & Chief Government Officer (612) 968-5236 [email protected] |
Katherine Kumar, PhD, RAC Senior Government Vice President (612) 716-5578 [email protected]
|
Source 4C Clinical Technologies, Inc.
